Jane A Mckeating

List of Publications by Year in Descending Order

191 papers	17,864 citations	67 h-index	132 g-index
203 ext. papers	19,702 ext. citations	8.2 avg, IF	6.21 L-index

#	Paper	IF	Citations
191	The role of circadian clock pathways in viral replication.. *Seminars in Immunopathology*, **2022**, 44, 175	12	2
190	Are the patterns of cytomegalovirus viral load seen after solid organ transplantation affected by circadian rhythm?. *Journal of Infectious Diseases*, **2022**,	7	1
189	The HCV Envelope Glycoprotein Down-Modulates NF-B Signalling and Associates With Stimulation of the Host Endoplasmic Reticulum Stress Pathway.. *Frontiers in Immunology*, **2022**, 13, 831695	8.4	
188	Hypoxia is more than HIFs.. *Journal of Hepatology*, **2022**,	13.4	
187	Acute intermittent hypoxia drives hepatic lipogenesis in humans and rodents.. *Metabolism Open*, **2022**, 14, 100177	2.8	0
186	Inflammatory Gene Expression Associates with Hepatitis B Virus cccDNA- but Not Integrant-Derived Transcripts in HBeAg Negative Disease. *Viruses*, **2022**, 14, 1070	6.2	1
185	Time of Day of Vaccination Affects SARS-CoV-2 Antibody Responses in an Observational Study of Health Care Workers. *Journal of Biological Rhythms*, **2021**, 7487304211059315	3.2	9
184	An immunodominant NP-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. *Nature Immunology*, **2021**,	19.1	19
183	Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure. *Nature Communications*, **2021**, 12, 6105	17.4	3
182	The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells **2021**,		2
181	A PCR assay to quantify patterns of HBV transcription. *Journal of General Virology*, **2021**, 102,	4.9	7
180	Circadian control of hepatitis B virus replication. *Nature Communications*, **2021**, 12, 1658	17.4	12
179	Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. *IScience*, **2021**, 24, 102367	6.1	34
178	Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. *Cell Reports*, **2021**, 35, 109020	10.6	22
177	Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. *Nature Communications*, **2021**, 12, 2814	17.4	10
176	Hypoxia inducible factors regulate hepatitis B virus replication by activating the basal core promoter. *Journal of Hepatology*, **2021**, 75, 64-73	13.4	10
175	Supramolecular Cylinders Target Bulge Structures in the 5RUTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication*. *Angewandte Chemie - International Edition*, **2021**, 60, 18144-18151	16.4	4

174	Supramolecular Cylinders Target Bulge Structures in the 5? UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication**. *Angewandte Chemie*, **2021**, 133, 18292-18299	3.6	1
173	Estimating hepatitis B virus cccDNA persistence in chronic infection. *Virus Evolution*, **2021**, 7, veaa063	3.7	8
172	The CCCTC-binding factor CTCF represses hepatitis B virus enhancer I and regulates viral transcription. *Cellular Microbiology*, **2021**, 23, e13274	3.9	5
171	The Circadian Clock and Viral Infections. *Journal of Biological Rhythms*, **2021**, 36, 9-22	3.2	24
170	Hypoxia-Inducible Factor 1 Alpha-Mediated RelB/APOBEC3B Down-regulation Allows Hepatitis B Virus Persistence. *Hepatology*, **2021**, 74, 1766-1781	11.2	7
169	The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells. *IScience*, **2021**, 24, 103144	6.1	9
168	Clocks, Viruses, and Immunity: Lessons for the COVID-19 Pandemic. *Journal of Biological Rhythms*, **2021**, 36, 23-34	3.2	15
167	A Role for B Cells to Transmit Hepatitis C Virus Infection.. *Frontiers in Immunology*, **2021**, 12, 775098	8.4	
166	Oxygen Sensing and Viral Replication: Implications for Tropism and Pathogenesis. *Viruses*, **2020**, 12,	6.2	5
165	Accurate targeted long-read DNA methylation and hydroxymethylation sequencing with TAPS. *Genome Biology*, **2020**, 21, 54	18.3	31
164	Cholesterol-modifying drugs in COVID-19. *Oxford Open Immunology*, **2020**, 1, iqaa001	4.8	14
163	Hypoxic microenvironment shapes HIV-1 replication and latency. *Communications Biology*, **2020**, 3, 376	6.7	8
162	Hypoxic gene expression in chronic hepatitis B virus infected patients is not observed in state-of-the-art in vitro and mouse infection models. *Scientific Reports*, **2020**, 10, 14101	4.9	8
161	Synchronised infection identifies early rate-limiting steps in the hepatitis B virus life cycle. *Cellular Microbiology*, **2020**, 22, e13250	3.9	9
160	Pharmacological activation of the circadian component REV-ERB inhibits HIV-1 replication. *Scientific Reports*, **2020**, 10, 13271	4.9	15
159	Insights From Deep Sequencing of the HBV Genome-Unique, Tiny, and Misunderstood. *Gastroenterology*, **2019**, 156, 384-399	13.3	60
158	The circadian clock components BMAL1 and REV-ERB regulate flavivirus replication. *Nature Communications*, **2019**, 10, 377	17.4	41
157	Bacterial flagellin promotes viral entry via an NF-kB and Toll Like Receptor 5 dependent pathway. *Scientific Reports*, **2019**, 9, 7903	4.9	9

156	A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus. *Value in Health*, **2019**, 22, 693-703	3.3	8
155	A dual role for SAMHD1 in regulating HBV cccDNA and RT-dependent particle genesis. *Life Science Alliance*, **2019**, 2,	5.8	10
154	Hepatitis C virus infection is associated with hepatic and adipose tissue insulin resistance that improves after viral cure. *Clinical Endocrinology*, **2019**, 90, 440-448	3.4	11
153	Hepatitis B virus genome recycling and de novo secondary infection events maintain stable cccDNA levels. *Journal of Hepatology*, **2018**, 69, 1231-1241	13.4	95
152	Daytime variation in hepatitis C virus replication kinetics following liver transplant. *Wellcome Open Research*, **2018**, 3, 96	4.8	7
151	Glucose and glutamine availability regulate HepG2 transcriptional responses to low oxygen. *Wellcome Open Research*, **2018**, 3, 126	4.8	5
150	Daytime variation in hepatitis C virus replication kinetics following liver transplant. *Wellcome Open Research*, **2018**, 3, 96	4.8	5
149	Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in cellulo. *Scientific Reports*, **2018**, 8, 13342	4.9	15
148	The Measles Virus Receptor SLAMF1 Can Mediate Particle Endocytosis. *Journal of Virology*, **2017**, 91,	6.6	24
147	Autotaxin-lysophosphatidic acid receptor signalling regulates hepatitis C virus replication. *Journal of Hepatology*, **2017**, 66, 919-929	13.4	39
146	Interplay between circadian clock and viral infection. *Journal of Molecular Medicine*, **2017**, 95, 1283-1289	5.5	33
145	N-Glycosylation of the Na+-Taurocholate Cotransporting Polypeptide (NTCP) Determines Its Trafficking and Stability and Is Required for Hepatitis B Virus Infection. *PLoS ONE*, **2017**, 12, e0170419	3.7	28
144	Glucocorticoids promote Von Hippel Lindau degradation and Hif-1 stabilization. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, 9948-9953	11.5	30
143	Viral hepatitis and liver cancer. *Philosophical Transactions of the Royal Society B: Biological Sciences*, **2017**, 372,	5.8	153
142	High resolution sequencing of hepatitis C virus reveals limited intra-hepatic compartmentalization in end-stage liver disease. *Journal of Hepatology*, **2017**, 66, 28-38	13.4	17
141	A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81. *Wellcome Open Research*, **2017**, 2, 82	4.8	13
140	TNF superfamily members promote hepatitis C virus entry via an NF-B and myosin light chain kinase dependent pathway. *Journal of General Virology*, **2017**, 98, 405-412	4.9	11
139	Solute Carrier NTCP Regulates Innate Antiviral Immune Responses Targeting Hepatitis C Virus Infection of Hepatocytes. *Cell Reports*, **2016**, 17, 1357-1368	10.6	29

138	Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. *Liver Transplantation*, **2016**, 22, 287-97	4.5	22
137	Deep sequencing of hepatitis C virus reveals genetic compartmentalization in cerebrospinal fluid from cognitively impaired patients. *Liver International*, **2016**, 36, 1418-24	7.9	14
136	Lentiviral hepatitis B pseudotype entry requires sodium taurocholate co-transporting polypeptide and additional hepatocyte-specific factors. *Journal of General Virology*, **2016**, 97, 121-127	4.9	15
135	A Comprehensive Analysis of the Impact of HIV on HCV Immune Responses and Its Association with Liver Disease Progression in a Unique Plasma Donor Cohort. *PLoS ONE*, **2016**, 11, e0158037	3.7	2
134	Monoclonal anti-envelope antibody AP33 protects humanized mice against a patient-derived hepatitis C virus challenge. *Hepatology*, **2016**, 63, 1120-34	11.2	26
133	Hepatitis C virus infection of cholangiocarcinoma cell lines. *Journal of General Virology*, **2015**, 96, 1380-1388	4.9	7
132	Permissivity of primary hepatocytes and hepatoma cell lines to support hepatitis C virus infection. *Journal of General Virology*, **2015**, 96, 1369-1373	4.9	2
131	Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody. *Nature Biotechnology*, **2015**, 33, 549-554	44.5	104
130	Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. *Journal of Virology*, **2015**, 89, 2170-81	6.6	62
129	Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant. *Journal of Virology*, **2015**, 89, 7758-75	6.6	17
128	The past, present and future of neutralizing antibodies for hepatitis C virus. *Antiviral Research*, **2014**, 105, 100-11	10.8	95
127	Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. *Journal of Virology*, **2014**, 88, 5502-10	6.6	45
126	Entry of hepatitis B and C viruses - recent progress and future impact. *Current Opinion in Virology*, **2014**, 4, 58-65	7.5	40
125	Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. *Hepatology*, **2014**, 59, 375-84	11.2	22
124	Polymersome-mediated delivery of combination anticancer therapy to head and neck cancer cells: 2D and 3D in vitro evaluation. *Molecular Pharmaceutics*, **2014**, 11, 1176-88	5.6	105
123	Hypoxia inducible factors in liver disease and hepatocellular carcinoma: current understanding and future directions. *Journal of Hepatology*, **2014**, 61, 1397-406	13.4	113
122	Activated macrophages promote hepatitis C virus entry in a tumor necrosis factor-dependent manner. *Hepatology*, **2014**, 59, 1320-30	11.2	38
121	Type I interferon rapidly restricts infectious hepatitis C virus particle genesis. *Hepatology*, **2014**, 60, 1891-901	11.2	4

120	A role for CD81 and hepatitis C virus in hepatoma mobility. *Viruses*, **2014**, 6, 1454-72	6.2	10
119	IGHV1-69 B cell chronic lymphocytic leukemia antibodies cross-react with HIV-1 and hepatitis C virus antigens as well as intestinal commensal bacteria. *PLoS ONE*, **2014**, 9, e90725	3.7	28
118	Hepatoma polarization limits CD81 and hepatitis C virus dynamics. *Cellular Microbiology*, **2013**, 15, 430-45	5.9	38
117	Early infection events highlight the limited transmissibility of hepatitis C virus in vitro. *Journal of Hepatology*, **2013**, 58, 1074-80	13.4	18
116	An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. *Hepatology*, **2013**, 58, 932-9	11.2	56
115	HRas signal transduction promotes hepatitis C virus cell entry by triggering assembly of the host tetraspanin receptor complex. *Cell Host and Microbe*, **2013**, 13, 302-13	23.4	123
114	A bile acid transporter as a candidate receptor for hepatitis B and D virus entry. *Journal of Hepatology*, **2013**, 58, 1246-8	13.4	10
113	IFITM1 is a tight junction protein that inhibits hepatitis C virus entry. *Hepatology*, **2013**, 57, 461-9	11.2	115
112	Functional analysis of claudin-6 and claudin-9 as entry factors for hepatitis C virus infection of human hepatocytes by using monoclonal antibodies. *Journal of Virology*, **2013**, 87, 10405-10	6.6	25
111	Heterogeneous claudin-1 expression in human liver. *Hepatology*, **2013**, 57, 854-5	11.2	3
110	Production, purification and characterization of recombinant, full-length human claudin-1. *PLoS ONE*, **2013**, 8, e64517	3.7	9
109	In silico directed mutagenesis identifies the CD81/claudin-1 hepatitis C virus receptor interface. *Cellular Microbiology*, **2012**, 14, 1892-903	3.9	30
108	Hepatitis C virus infects the endothelial cells of the blood-brain barrier. *Gastroenterology*, **2012**, 142, 634-643.e6	13.3	161
107	A dual role for hypoxia inducible factor-1α in the hepatitis C virus lifecycle and hepatoma migration. *Journal of Hepatology*, **2012**, 56, 803-9	13.4	65
106	Bioportide: an emergent concept of bioactive cell-penetrating peptides. *Cellular and Molecular Life Sciences*, **2012**, 69, 2951-66	10.3	30
105	Hepatitis C virus entry: beyond receptors. *Reviews in Medical Virology*, **2012**, 22, 182-93	11.7	71
104	Hepatitis C virus induces CD81 and claudin-1 endocytosis. *Journal of Virology*, **2012**, 86, 4305-16	6.6	99
103	Hepatitis C virus envelope glycoprotein fitness defines virus population composition following transmission to a new host. *Journal of Virology*, **2012**, 86, 11956-66	6.6	30

102	Naturally occurring antibodies that recognize linear epitopes in the amino terminus of the hepatitis C virus E2 protein confer noninterfering, additive neutralization. *Journal of Virology*, **2012**, 86, 2739-49	6.6	48
101	Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors. *Journal of Hepatology*, **2011**, 54, 48-55	13.4	112
100	EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. *Nature Medicine*, **2011**, 17, 589-95	50.5	511
99	Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion on virus infectivity. *PLoS ONE*, **2011**, 6, e25789	3.7	5
98	Hepatitis C virus targets the T cell secretory machinery as a mechanism of immune evasion. *Hepatology*, **2011**, 53, 1846-53	11.2	14
97	Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. *Journal of Virology*, **2011**, 85, 596-605	6.6	186
96	Hepatitis C virus entry and the tetraspanin CD81. *Biochemical Society Transactions*, **2011**, 39, 532-6	5.1	37
95	Structural characterization of CD81-Claudin-1 hepatitis C virus receptor complexes. *Biochemical Society Transactions*, **2011**, 39, 537-40	5.1	5
94	Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. *Journal of Infectious Diseases*, **2011**, 204, 811-3	7	43
93	Claudin association with CD81 defines hepatitis C virus entry. *Journal of Biological Chemistry*, **2010**, 285, 21092-102	5.4	166
92	Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner. *Gastroenterology*, **2010**, 138, 1134-42	13.3	62
91	Monoclonal anti-claudin 1 antibodies prevent hepatitis C virus infection of primary human hepatocytes. *Gastroenterology*, **2010**, 139, 953-64, 964.e1-4	13.3	132
90	Hepatitis C virus infection of neuroepithelioma cell lines. *Gastroenterology*, **2010**, 139, 1365-74	13.3	51
89	The Involvement of Tight Junction Protein Claudin-1 in Hepatitis C Virus Entry. *Current Topics in Membranes*, **2010**, 65, 273-292	2.2	1
88	Mechanisms of viral entry: sneaking in the front door. *Protoplasma*, **2010**, 244, 15-24	3.4	39
87	Development of novel therapies for hepatitis C. *Antiviral Research*, **2010**, 86, 79-92	10.8	66
86	Inhibition of hepatitis C virus infection by anti-claudin-1 antibodies is mediated by neutralization of E2-CD81-claudin-1 associations. *Hepatology*, **2010**, 51, 1144-57	11.2	130
85	Multiple effects of silymarin on the hepatitis C virus lifecycle. *Hepatology*, **2010**, 51, 1912-21	11.2	159

84	Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity. *Journal of Virology*, **2009**, 83, 6149-60	6.6	75
83	Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. *Journal of Virology*, **2009**, 83, 6211-21	6.6	104
82	Hepatoma cell density promotes claudin-1 and scavenger receptor BI expression and hepatitis C virus internalization. *Journal of Virology*, **2009**, 83, 12407-14	6.6	36
81	The complexities of hepatitis C virus entry. *Journal of Hepatology*, **2009**, 51, 609-11	13.4	8
80	Hepatitis C virus association with peripheral blood B lymphocytes potentiates viral infection of liver-derived hepatoma cells. *Blood*, **2009**, 113, 585-93	2.2	64
79	Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. *Nature Medicine*, **2008**, 14, 25-7	50.5	466
78	Structural characterization of recombinant human CD81 produced in Pichia pastoris. *Protein Expression and Purification*, **2008**, 57, 206-16	2	27
77	Hepatitis C virus entry and neutralization. *Clinics in Liver Disease*, **2008**, 12, 693-712, x	4.6	40
76	Protein kinase A-dependent step(s) in hepatitis C virus entry and infectivity. *Journal of Virology*, **2008**, 82, 8797-811	6.6	81
75	Identification of a residue in hepatitis C virus E2 glycoprotein that determines scavenger receptor BI and CD81 receptor dependency and sensitivity to neutralizing antibodies. *Journal of Virology*, **2008**, 82, 12020-9	6.6	137
74	Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. *Journal of Infectious Diseases*, **2008**, 198, 203-12	7	52
73	CD81 and claudin 1 coreceptor association: role in hepatitis C virus entry. *Journal of Virology*, **2008**, 82, 5007-20	6.6	154
72	In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 19450-5	11.5	64
71	Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. *Journal of Virology*, **2008**, 82, 569-74	6.6	121
70	Effect of cell polarization on hepatitis C virus entry. *Journal of Virology*, **2008**, 82, 461-70	6.6	98
69	Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. *Hepatology*, **2008**, 47, 17-24	11.2	277
68	Hepatitis C virus receptor expression in normal and diseased liver tissue. *Hepatology*, **2008**, 47, 418-27	11.2	82
67	The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. *Journal of Virology*, **2007**, 81, 8101-11	6.6	169

66	Discordant role of CD4 T-cell response relative to neutralizing antibody and CD8 T-cell responses in acute hepatitis C. *Gastroenterology*, **2007**, 132, 654-66	13.3	129
65	Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. *Gastroenterology*, **2007**, 132, 667-78	13.3	319
64	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. *Nature*, **2007**, 446, 801-5	50.4	970
63	Superinfection exclusion in cells infected with hepatitis C virus. *Journal of Virology*, **2007**, 81, 3693-703	6.6	119
62	Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity. *Journal of Virology*, **2007**, 81, 3162-9	6.6	126
61	Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I. *Journal of Virology*, **2007**, 81, 374-83	6.6	218
60	Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. *Blood*, **2007**, 109, 845-6	2.2	48
59	Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. *Vaccine*, **2007**, 25, 7773-84	4.1	70
58	Hepatitis C is associated with perturbation of intrahepatic myeloid and plasmacytoid dendritic cell function. *Journal of Hepatology*, **2007**, 47, 338-47	13.4	59
57	Oxidized low-density lipoprotein inhibits hepatitis C virus cell entry in human hepatoma cells. *Hepatology*, **2006**, 43, 932-42	11.2	108
56	Diverse CD81 proteins support hepatitis C virus infection. *Journal of Virology*, **2006**, 80, 11331-42	6.6	128
55	Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. *Journal of Virology*, **2006**, 80, 1734-41	6.6	318
54	Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. *Journal of Virology*, **2006**, 80, 2832-41	6.6	162
53	Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 3805-9	11.5	375
52	Persistent hepatitis C virus infection in vitro: coevolution of virus and host. *Journal of Virology*, **2006**, 80, 11082-93	6.6	218
51	Expression of DC-SIGN and DC-SIGNR on human sinusoidal endothelium: a role for capturing hepatitis C virus particles. *American Journal of Pathology*, **2006**, 169, 200-8	5.8	84
50	Complete replication of hepatitis C virus in cell culture. *Science*, **2005**, 309, 623-6	33.3	1904
49	Humoral immune response in acute hepatitis C virus infection. *Clinical Infectious Diseases*, **2005**, 41, 667-75	7.6	148

48	CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. *Journal of Virology*, **2004**, 78, 1448-55	6.6	295
47	Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. *Journal of Virology*, **2004**, 78, 6875-82	6.6	81
46	Neutralizing antibody response during acute and chronic hepatitis C virus infection. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 10149-54	11.5	328
45	Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. *Journal of Virology*, **2004**, 78, 8496-505	6.6	139
44	Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. *Journal of Virology*, **2003**, 77, 4070-80	6.6	321
43	Efficient replication of hepatitis C virus genotype 1a RNAs in cell culture. *Journal of Virology*, **2003**, 77, 3181-90	6.6	289
42	Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. *Journal of Virology*, **2003**, 77, 1856-67	6.6	140
41	Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 7271-6	11.5	666
40	Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. *Journal of Virology*, **2002**, 76, 13001-14	6.6	984
39	Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization. *Journal of Virology*, **2001**, 75, 5593-603	6.6	8
38	Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. *Journal of General Virology*, **2001**, 82, 1877-1883	4.9	153
37	Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. *Journal of Virology*, **2000**, 74, 3642-9	6.6	187
36	The role of the hepatitis C virus glycoproteins in infection. *Reviews in Medical Virology*, **2000**, 10, 101-17	11.7	57
35	Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity. *Virology*, **2000**, 273, 60-6	3.6	26
34	Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. *Journal of Virology*, **2000**, 74, 702-9	6.6	101
33	Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. *Journal of Virology*, **2000**, 74, 5933-8	6.6	85
32	Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES. Characterization of active disaggregated chemokine variants. *Journal of Biological Chemistry*, **1999**, 274, 16077-84	5.4	133
31	The role of the viral glycoprotein in HIV-1 persistence. *Immunology Letters*, **1999**, 65, 63-70	4.1	5

30	Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. *Journal of Virology*, **1999**, 73, 6235-44	6.6	381
29	Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. *Journal of Virology*, **1999**, 73, 6782-90	6.6	141
28	The C-terminal region of the hepatitis C virus E1 glycoprotein confers localization within the endoplasmic reticulum. *Journal of General Virology*, **1999**, 80 (Pt 8), 1943-1947	4.9	40
27	The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein. *Virology*, **1998**, 251, 59-70	3.6	1
26	Mutant CD4 molecules with improved binding to HIV envelope protein gp120 selected by phage display. *Virology*, **1997**, 234, 196-202	3.6	3
25	Passage of HIV-1 molecular clones into different cell lines confers differential sensitivity to neutralization. *Virology*, **1997**, 238, 254-64	3.6	32
24	The role of the humoral immune response in HIV infection. *Aids*, **1996**, 10 Suppl A, S97-106	3.5	25
23	Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera. *Virology*, **1996**, 220, 450-60	3.6	21
22	Immunogenicity of full length and truncated forms of the human immunodeficiency virus type I envelope glycoprotein. *Immunology Letters*, **1996**, 51, 101-5	4.1	21
21	Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization. *AIDS Research and Human Retroviruses*, **1993**, 9, 595-604	1.6	17
20	An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. *Virology*, **1993**, 196, 332-7	3.6	40
19	Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site. *AIDS Research and Human Retroviruses*, **1992**, 8, 451-9	1.6	34
18	Neutralization of human immunodeficiency virus. *Reviews in Medical Virology*, **1992**, 2, 35-42	11.7	7
17	Synergistic interaction between ligands binding to the CD4 binding site and V3 domain of human immunodeficiency virus type I gp120. *Virology*, **1992**, 191, 732-42	3.6	90
16	The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion?. *AIDS Research and Human Retroviruses*, **1991**, 7, 3-16	1.6	241
15	Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro. *Virology*, **1991**, 185, 72-9	3.6	53
14	HIV infectivity. *Nature*, **1991**, 349, 660	50.4	10
13	Response : Receptor-Mediated Activation of Immunodeficiency Viruses in Viral Fusion. *Science*, **1991**, 252, 1322-1323	33.3	4

12	Response : Receptor-Mediated Activation of Immunodeficiency Viruses in Viral Fusion. *Science*, **1991**, 252, 1322-1323	33.3	1
11	Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4. *Aids*, **1990**, 4, 307-15	3.5	108
10	An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. *Nature*, **1989**, 339, 385-8, 340	50.4	207
9	Structure and function of the HIV envelope. *Aids*, **1989**, 3 Suppl 1, S35-41	3.5	66
8	An enzyme-linked immunosorbent assay for antibodies to the envelope glycoproteins of divergent strains of HIV-1. *Aids*, **1989**, 3, 155-63	3.5	62
7	Characterization of HIV-1 neutralization escape mutants. *Aids*, **1989**, 3, 777-84	3.5	181
6	Enhancement of class I HLA antigen expression by cytomegalovirus: role in amplification of virus infection. *Journal of Medical Virology*, **1988**, 25, 483-95	19.7	62
5	Identification of a monoclonal antibody to abscission tissue that recognises xylose/fucose-containing N-linked oligosaccharides from higher plants. *Planta*, **1988**, 175, 506-12	4.7	79
4	Time of day of vaccination affects SARS-CoV-2 antibody responses in an observational study of healthcare workers		1
3	Estimating hepatitis B virus cccDNA persistence in chronic infection		2
2	Synchronized infection identifies early rate-limiting steps in the hepatitis B virus life cycle		1
1	Absolute quantitation of individual SARS-CoV-2 RNA molecules: a new paradigm for infection dynamics and variant differences		2